PROGNOSTIC FACTORS IN STEREOTACTIC BODY RADIOTHERAPY FOR NON-SMALL-CELL LUNG CANCER

被引:100
作者
Matsuo, Yukinori [1 ]
Shibuya, Keiko
Nagata, Yasushi [2 ]
Takayama, Kenji
Norihisa, Yoshiki
Mizowaki, Takashi
Narabayashi, Masaru
Sakanaka, Katsuyuki
Hiraoka, Masahiro
机构
[1] Kyoto Univ, Dept Radiat Oncol & Image Appl Therapy, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan
[2] Hiroshima Univ Hosp, Div Radiat Oncol, Hiroshima, Japan
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2011年 / 79卷 / 04期
关键词
SBRT; Lung cancer; Prognostic factor; STAGE-I; RADIATION-THERAPY; CLINICAL-OUTCOMES; TREATMENT TIME; PHASE-II; SURVIVAL; CARCINOMA; IMPACT; WOMEN; TRIAL;
D O I
10.1016/j.ijrobp.2009.12.022
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose: To investigate the factors that influence clinical outcomes after stereotactic body radiotherapy (SBRT) for non small-cell lung cancer (NSCLC). Methods and Materials: A total of 101 consecutive patients who underwent SBRT with 48 Gy in 4 fractions for histologically confirmed Stage I NSCLC were enrolled in this study. Factors including age, maximal tumor diameter, sex, performance status, operability, histology, and overall treatment time were evaluated with regard to local progression (LP), disease progression (DP), and overall survival (OS) using the Cox proportional hazards model. Prognostic models were built with recursive partitioning analysis. Results: Three-year OS was 58.6% with a median follow-up of 31.4 months. Cumulative incidence rates of LP and DP were 13.2% and 40.8% at 3 years, respectively. Multivariate analysis demonstrated that tumor diameter was a significant factor in all endpoints of LP, DP, and OS. Other significant factors were age in DP and sex in OS. Recursive partitioning analysis indicated a condition for good prognosis (Class I) as follows: female or T1a (tumor diameter <= 20 mm). When the remaining male patients with T1b-2a (> 20 mm) were defined as Class II, 3-year LP, DP, and OS were 6.8%, 23.6%, and 69.9% in recursive partitioning analysis Class I, respectively, whereas these values were 19.9%, 58.3%, and 47.1% in Class II. The differences between the classes were statistically significant. Conclusions: Tumor diameter and sex were the most significant factors in SBRT for NSCLC. T1a or female patients had good prognosis. (C) 2011 Elsevier Inc.
引用
收藏
页码:1104 / 1111
页数:8
相关论文
共 40 条
[1]
Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries [J].
Baumann, Pia ;
Nyman, Jan ;
Lax, Ingmar ;
Friesland, Signe ;
Hoyer, Morten ;
Ericsson, Suzanne Rehn ;
Johansson, Karl-Axel ;
Ekberg, Lars ;
Morhed, Elisabeth ;
Paludan, Merete ;
Wittgren, Lena ;
Blomgren, Henrik ;
Lewensohn, Rolf .
ACTA ONCOLOGICA, 2006, 45 (07) :787-795
[2]
Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy [J].
Baumann, Pia ;
Nyman, Jan ;
Hoyer, Morten ;
Wennberg, Berit ;
Gagliardi, Giovanna ;
Lax, Ingmar ;
Drugge, Ninni ;
Ekberg, Lars ;
Friesland, Signe ;
Johansson, Karl-Axel ;
Lund, Jo-Asmund ;
Morhed, Elisabeth ;
Nilsson, Kristina ;
Levin, Nina ;
Paludan, Merete ;
Sederholm, Christer ;
Traberg, Anders ;
Wittgren, Lena ;
Lewensohn, Rolf .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) :3290-3296
[3]
STEREOTAXIC HIGH-DOSE FRACTION RADIATION-THERAPY OF EXTRACRANIAL TUMORS USING AN ACCELERATOR - CLINICAL-EXPERIENCE OF THE FIRST 31 PATIENTS [J].
BLOMGREN, H ;
LAX, I ;
NASLUND, I ;
SVANSTROM, R .
ACTA ONCOLOGICA, 1995, 34 (06) :861-870
[4]
The impact of overall treatment time on outcomes in radiation therapy for non-small cell lung cancer [J].
Chen, M ;
Jiang, GL ;
Fu, XL ;
Wang, LJ ;
Qian, H ;
Chen, GY ;
Zhao, S ;
Liu, TF .
LUNG CANCER, 2000, 28 (01) :11-19
[5]
STEREOTACTIC BODY RADIATION THERAPY FOR EARLY-STAGE NON-SMALL-CELL LUNG CARCINOMA: FOUR-YEAR RESULTS OF A PROSPECTIVE PHASE II STUDY [J].
Fakiris, Achilles J. ;
McGarry, Ronald C. ;
Yiannoutsos, Constantin T. ;
Papiez, Lech ;
Williams, Mark ;
Henderson, Mark A. ;
Timmerman, Robert .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03) :677-682
[6]
Prospective study on stereotactic radiotherapy of limited-stage non-small-cell lung cancer [J].
Hoyer, Morten ;
Roed, Henrik ;
Hansen, Anders Traberg ;
Ohlhuis, Lars ;
Petersen, Jorgen ;
Nellemann, Hanne ;
Berthelsen, Anne Kiil ;
Grau, Cai ;
Engelholm, Svend Aage ;
Von Der Maase, Hans .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (04) :S128-S135
[7]
Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21387]
[8]
Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution [J].
Kameyama, Kotaro ;
Takahashi, Mamoru ;
Ohata, Keiji ;
Igai, Hitoshi ;
Yamashina, Akihiko ;
Matsuoka, Tomoaki ;
Nakagawa, Tatsuo ;
Okumura, Norihito .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2009, 137 (05) :1180-1184
[9]
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung [J].
Kato, H ;
Ichinose, Y ;
Ohta, M ;
Hata, E ;
Tsubota, N ;
Tada, H ;
Watanabe, Y ;
Wada, H ;
Tsuboi, M ;
Hamajima, N ;
Ohta, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (17) :1713-1721
[10]
KATO H, 2008, CANC STAT JAPAN 2008